Gilead Sciences (GILD) Misses Q1 EPS by 288c
Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of ($1.32), $2.88 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $6.65 billion versus the consensus estimate of $6.36 billion.
GUIDANCE:
Gilead Sciences sees FY2024 EPS of $3.45-$3.85, versus the consensus of $3.67.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.